Table 2

Primary prophylaxis with G-CSF used by physician: overall and according to medical specialty

Population analysed (n=205)Medical oncologist (n=123)Pulmonologist (oncology certified) (n=41)Gastroenterologist (oncology certified) (n=41)
Patients initiating G-CSF as primary prophylaxis during chemotherapy (%)
Mean (±SD)32 (±20)35 (±21)27 (±21)25.4 (±14)
Median (range)25 (5–95)30 (5–90)20 (5–95)20 (10–60)
Proportions classified, n (%)
 <25%97 (47)49 (40)25 (61)23 (56)
 25%–75%99 (48)68 (55)13 (32)18 (44)
 >75%9 (4)6 (5)3 (7)0 (0)
In patients initiating primary prophylaxis
Proportion of patients prescribed filgrastim (%)
Mean (±SD)46 (±27)47 (±26)41 (±31)50 (±29)
Median (range)50 (0–100)50 (0–100)30 (0–100)50 (0–100)
Proportions classified, n (%)
 <25%49 (24)26 (21)16 (40)7 (17)
 25%–75%121 (59)79 (64)16 (40)26 (63)
 >75%34 (17)18 (15)8 (20)8 (20)
 Missing data1010
Proportion of patients prescribed pegfilgrastim (%)
Mean (±SD)54 (±27)53 (±26)59 (±31)50 (±29)
Median (range)50 (0–100)50 (0–100)70 (0–100)50 (0–100)
Proportions classified, n (%)
 <25%34 (17)18 (15)8 (20)8 (20)
 25%–75%121 (59)79 (64)16 (40)26 (63)
 >75%49 (24)26 (21)16 (40)7 (17)
 Missing data1010
  • G-CSF, granulocyte colony-stimulating factors.